|
Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off
|
25 August 2022 |
|
New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
|
28 June 2022 |
|
Novartis announces Nature Medicine publication of Zolgensma data demonstrating age-appropriate milestones when treating children with SMA presymptomatically
|
20 June 2022 |
|
Sandoz announces new global 'Act4Biosimilars' initiative
|
03 June 2022 |
|
Novartis provides more than USD 25 million in medical aid to patients in Ukraine and bordering countries
|
22 April 2022 |
|
Novartis announces new organizational structure
|
05 April 2022 |
|
Novartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy
|
10 March 2022 |
|
Novartis, Voyager Therapeutics reach license option agreement for next-generation gene therapy vectors for neurological diseases
|
08 March 2022 |
|
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
|
12 January 2022 |
|
Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021
|
16 December 2021 |